Q0180 Insurance Policy Changes

HCPCS Q0180 is officially defined as "Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen." No tracked policy changes reference HCPCS Q0180 yet. New payer updates are added daily, so check back soon or create a free alert to be notified the moment a change affects this code.